Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

http://www.reportlinker.com/p0866960/Arthritis-Therapeutics-Market-to-2018---Novel-Oral-JAK-Inhibitors-and-Biologic-Disease-Modifying-Anti-Rheumatic-Drugs-DMARD-Will-Drive-Continued-Growth-Across-Key-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a $38 billion. The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010. The rheumatoid arthritis market was $14 billion in 2010. The market revenue is expected to increase to $26.9 billion by 2018 at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications. Top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

GBI Research analysis shows that the Research and Development (R&D) pipeline for the arthritis therapeutics market is strong. The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

Scope

- Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market - The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.- Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.- Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.- Develop key strategic initiatives by understanding the key focus areas of the leading companies.- Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 112 Arthritis Therapeutics Market to 2018 - Introduction 123 Arthritis Therapeutics Market to 2018 - Market Overview 143.1 Introduction 143.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 153.2.1 Revenue 153.2.2 Annual Cost of Treatment 163.3 Treatment Usage Patterns 173.3.1 Diseased Population 183.3.2 Treatment Seeking Population 183.3.3 Diagnosis Population 183.3.4 Prescription Population 194 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape 204.1 Osteoarthritis Therapeutics Market 204.1.1 Introduction 204.1.2 Epidemiology 214.1.3 Symptoms 214.1.4 Diagnosis 214.1.5 Diagnostic Imaging Techniques 224.1.6 Treatment 224.1.7 Revenue 254.1.8 Annual Cost of Treatment 264.1.9 Treatment Usage Patterns 274.1.10 Marketed Products 294.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 304.2.1 Drivers for the Osteoarthritis Therapeutics Market 304.2.2 Barriers for the Osteoarthritis Therapeutics Market 304.3 Opportunity and Unmet Need 314.4 Arthritis Therapeutics Market 324.4.1 Introduction 324.4.2 Epidemiology 334.4.3 Symptoms 334.4.4 Diagnosis 344.4.5 Diagnostic Techniques 344.4.6 Treatment 354.4.7 Non-Pharmacological Therapy 364.4.8 Surgical Treatment 364.4.9 Pharmacological Therapy 364.4.10 Revenue 374.4.11 Annual Cost of Treatment 384.4.12 Treatment Usage Patterns 394.4.13 Marketed products 414.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 424.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 424.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 424.6 Opportunity and Unmet Needs 434.7 Psoriatic Arthritis Therapeutics Market 434.7.1 Introduction 434.7.2 Epidemiology 444.7.3 Symptoms 444.7.4 Diagnosis 444.7.5 Diagnostic Techniques 444.7.6 Treatment 454.7.7 Non-Pharmacological Therapy 454.7.8 Pharmacological Therapy 454.7.9 Surgery 464.7.10 Revenue 464.7.11 Annual Cost of Treatment 474.7.12 Treatment Usage Patterns 484.7.13 Marketed Products 504.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 514.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 514.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 514.9 Opportunity and Unmet Needs 514.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market 524.10.1 Introduction 524.10.2 Epidemiology 524.10.3 Symptoms 534.10.4 Diagnosis 534.10.5 Treatment 544.10.6 Non-Pharmacological Therapy 544.10.7 Pharmacological Therapy 554.10.8 Surgery 564.10.9 Revenue 564.10.10 Annual Cost of Treatment 574.10.11 Treatment Usage Patterns 584.10.12 Marketed products 604.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 604.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 604.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 604.12 Opportunity and Unmet Need 615 Arthritis Therapeutics Market to 2018 - Geographical Landscape 625.1 Revenue Analysis by Geography 625.2 The US 635.2.1 Revenue 635.2.2 Annual Cost of Treatment 655.2.3 Treatment Usage Patterns 665.3 Top Five European countries (UK, Germany, France, Italy and Spain) 685.3.1 Revenue 685.3.2 Annual Cost of Treatment 695.3.3 Treatment Usage Patterns 705.4 Japan 725.4.1 Revenue 725.4.2 Annual Cost of Treatment 735.4.3 Treatment Usage Patterns 746 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis 766.1 Introduction 786.1.1 Research and Development Pipeline – Osteoarthritis 786.2 Introduction 836.2.1 Research and Development Pipeline – Rheumatoid Arthritis 836.3 Introduction 956.3.1 Research and Development Pipeline – Psoriasis Arthritis 956.4 Introduction 966.4.1 Research and Development Pipeline – Ankylosing Spondylitis 966.5 Profiles of Promising Drugs in the Pipeline 986.5.1 Tofacitinib (CP-690550) 986.5.2 Ofatumumab 996.5.3 Secukinumab (AIN457) 996.5.4 Fostamatinib (R788) 1006.5.5 LY2127399 (Tabalumab) 1016.5.6 REGN88 (SAR153191) 1026.5.7 LT-NS001 1037 Arthritis Therapeutics Market to 2018 - Competitive Landscape 1047.1 Market Share Analysis 1047.1.1 Major Players 1047.2 Competitive Profile 1057.2.1 Roche 1057.2.2 Johnson & Johnson 1077.2.3 Pfizer 1087.2.4 Abbott Laboratories 1107.2.5 Bristol-Myers Squibb 1117.2.6 Amgen 1128 Arthritis Therapeutics Market to 2018 - Strategic Consolidations 1138.1 Mergers and Acquisitions 1138.1.1 Overview 1138.1.2 Major Merger and Acquisition Deals 1138.1.3 Possible Future Merger and Acquisition Deals 1198.2 Licensing Agreements 1208.2.1 Overview 1208.2.2 Major Licensing Deal 1208.3 Co-Development Agreements 1268.4 Deals by Geography 1328.5 Deals by Value 1339 Arthritis Therapeutics Market to 2018 - Appendix 1349.1 Market Definitions 1349.2 Abbreviations 1349.3 Sources 1359.4 Research Methodology 1369.4.1 Coverage 1369.4.2 Secondary Research 1369.4.3 Primary Research 1379.4.4 Forecasts 1379.4.5 Expert Panel Validation 1409.5 Contact Us 1409.6 Disclaimer 140

List of Tables

Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 16

Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 16

Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 17

Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 17

Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 18

Table 7 : Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 25

Table 8: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 26

Table 9: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 26

Table 10: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 26

Table 11: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 27

Table 12: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 28

Table 13: Osteoarthritis Therapeutics Market, Marketed Products, 2010 29

Table 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 37

Table 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 37

Table 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 38

Table 17: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 38

Table 18: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 39

Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 40

Table 20: Rheumatoid Arthritis Therapeutics-Marketed Products, 2010 41

Table 21: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 47

Table 22: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 47

Table 23: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 47

Table 24: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 48

Table 25: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 49

Table 26: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 49

Table 27: Psoriatic Arthritis Therapeutics-Marketed Products, 2010 50

Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56

Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56

Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57

Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57

Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58

Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59

Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60

Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63

Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63

Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64

Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64

Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65

Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65

Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66

Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66

Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68

Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68

Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69

Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69

Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70

Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71

Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72

Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72

Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73

Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73

Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74

Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74

Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79

Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80

Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80

Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81

Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82

Table 60: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82

Table 61: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 84

Table 62: Arthritis Therapeutics Market, Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 85

Table 63: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 86

Table 64: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 87

Table 65: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 88

Table 66: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 89

Table 67: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 90

Table 68: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 92

Table 69: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 93

Table 70: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 94

Table 71: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 95

Table 72: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 96

Table 73: Arthritis Therapeutics Market- Ankylosing Spondylitis Pipeline, Development Stage Molecules, 2011 97

List of Figures

Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 16

Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 17

Figure 4: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 25

Figure 5: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 26

Figure 6: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 27

Figure 7: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 37

Figure 8: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 38

Figure 9: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 39

Figure 10: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 46

Figure 11: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 47

Figure 12: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 48

Figure 13: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 56

Figure 14: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 57

Figure 15: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 58

Figure 16: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2018 62

Figure 17: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 64

Figure 18: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018 65

Figure 19: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2018 66

Figure 20: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2004-2018 68

Figure 21: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2018 69

Figure 22: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2018 70

Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2004-2018 72

Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018 73

Figure 25:Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2018 74

Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76

Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77

Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78

Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83

Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95

Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96

Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104

Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106

Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107

Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109

Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110

Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111

Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112

Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132

Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133

Figure 41: GBI Research Market Forecasting Model 139

Companies Mentioned

Johnson & Johnson

Pfizer

Abbott Laboratories

Bristol-Myers Squibb

Amgen

To order this report:Therapy Industry: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

__________________________

Contact Clare:
[email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker